GlyT1 inhibition by ALX-5407 attenuates allograft rejection through suppression of Th1 cell differentiation
GlyT1 serves as a metabolic checkpoint in Th1 differentiation, and its inhibition by ALX-5407 attenuates allograft rejection through dual suppression of Th1 function and apoptosis induction. Synergy with rapamycin highlights a novel combinatorial strategy to mitigate rejection with reduced toxicity. These findings position GlyT1 targeting as a promising approach for clinical translation in transplantation immunotherapy.
Authors
- Jie Zhao (ORCID: https://orcid.org/0000-0002-6450-5046)
- Shuai Jin (ORCID: https://orcid.org/0000-0003-4314-1834)
- Jianghao Wei
- Gang Feng (ORCID: https://orcid.org/0000-0003-3504-775X)
- Zhen Wang (ORCID: https://orcid.org/0000-0002-2725-8322)
- Xiaohan Zhang (ORCID: https://orcid.org/0000-0002-4821-9795)
- Hui Wang (ORCID: https://orcid.org/0000-0002-2454-3814)
- Weiqi Zhang (ORCID: https://orcid.org/0000-0002-8885-5104)
Institutions
- Tianjin First Center Hospital (CN)
- Tianjin Medical University (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-09-23
- DOI
- https://doi.org/10.3389/fimmu.2025.1644529
- Primary Topic
- Epigenetics and DNA Methylation
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Chinese Academy of Medical Sciences
- Natural Science Foundation of Tianjin City